Neurotrophic therapy in the treatment of a comorbid patient with cerebrovascular pathology and diabetes mellitus

Kurushina O.V.; Barulin A.E.; Chernovolenko E.P.

doi:https://doi.org/10.17116/jnevro2022122081112

Kurushina O.V.

Volgograd State Medical University

SPIN RSCI: 4571-5646
Scopus AuthorID: 37008504700
ORCID: 0000-0003-4364-0123

Barulin A.E.

Volgograd State Medical University

SPIN RSCI: 6234-6783
Scopus AuthorID: 55657672800
ORCID: 0000-0001-7264-3580

Chernovolenko E.P.

Volgograd State Medical University

Neurotrophic therapy in the treatment of a comorbid patient with cerebrovascular pathology and diabetes mellitus

Authors:

Kurushina O.V., Barulin A.E., Chernovolenko E.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8): 112‑119

DOI: 10.17116/jnevro2022122081112

Read: 2036 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kurushina OV, Barulin AE, Chernovolenko EP. Neurotrophic therapy in the treatment of a comorbid patient with cerebrovascular pathology and diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(8):112‑119. (In Russ.)
https://doi.org/10.17116/jnevro2022122081112

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To study the use of Cellex in a population of patients aged 45 to 75 years with ischemic stroke and TIA, with a history of type 2 diabetes mellitus (T2DM), with diabetic distal symmetric polyneuropathy.

MATERIAL AND METHODS

The study involved 80 patients (men — 52.5%, women — 47.5%) in the rehabilitation period of stroke, including TIA, developed in T2DM. The patients were divided into 2 groups (40 people in each): in the 1st group, patients received Cellex 1.0 ml subcutaneously 1 time per day in addition to routine practice; the 2nd group received only routine practice. Cellex was prescribed in the form of two 10-day treatment courses with a break of 1 month. The range of patients examination during the whole study period (4 visits, 65 days) included an assessment of neurological symptoms (NIHSS, NISLL, DN-4, TSS scales), neurophysiological examination (EMNG), analysis of daily activity (SF-36 questionnaire, the Rivermead Mobility Index, the Modified Rankin Scale), the emotional state assessment on the scale and the effects of therapy on the Clinical Global Impression Scale.

RESULTS AND CONCLUSION

The clinical efficacy of the drug was shown in the form of an improvement of clinical parameters and data on EMNG of the lower extremities on the 60th day of the study. Improvement was observed in 17.5% of patients in the 1st group, while in the 2nd group deterioration was observed in 15.0% of patients, as evidenced by the presence of statistically significant differences. The study drug was also shown to be well tolerated and safe.

CONCLUSION

The use of the Cellex is effective and safe in patients with T2DM in the recovery period of stroke.

Keywords:

cerebrovascular diseases

stroke

diabetic distal symmetric polyneuropathy (DSPN)

diabetes mellitus (DM)

neuroprotectors

Cellex

Authors:

Kurushina O.V.

Volgograd State Medical University

SPIN RSCI: 4571-5646
Scopus AuthorID: 37008504700
ORCID: 0000-0003-4364-0123

Barulin A.E.

Volgograd State Medical University

SPIN RSCI: 6234-6783
Scopus AuthorID: 55657672800
ORCID: 0000-0001-7264-3580

Chernovolenko E.P.

Volgograd State Medical University

Received:

04.05.2022

Close metadata

References:

Antonova KV, Lagoda OV, Tanashyan MM. Cerebrovascular diseases and diabetic polyneuropathy in patients with diabetes: common pathogenetic mechanisms and approaches to management. Nervous Diseases. 2019;1:23-28. (In Russ.).
Piradov MA, Maksimova MYu, Tanashyan MM. Stroke. Step-by-step instructions, 2nd ed., additional. M.: GEOTAR-Media, 2020:19. (In Russ.).
Amelina IP, Solovieva EYu. Comorbid patient with diabetic neuropathy and cerebrovascular disease. Nervous Diseases. 2018;4:21-28. (In Russ.).
Chen R, Ovbiagele B, Feng W. Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci. 2016;351(4): 380-386. https://doi.org/10.1016/j.amjms.2016.01.011
Antonova KV, Medvedev RB, Shabalina AA, et al. Carbohydrate metabolism disorders and cerebral atherosclerosis in patients with ischemic cerebrovascular diseases. Annals of Clinical and Experimental Neurology. 2016;10(1):20-26. (In Russ.).
Kotova OV, Akarachkova ES, Belyaev AA. Neurological complications of diabetes mellitus. Medical Council. 2019;9:40-44. (In Russ.). https://doi.org/10.21518/2079-701X-2019-9-40-44
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013 Jan;93(1):137-188. https://doi.org/10.1152/physrev.00045.2011
Kurushina OV, Barulin AE, Chernovolenko EP. Alcoholic polyneuropathy: ways of diagnostics and therapy. Medical Council. 2019;1:58-63. (In Russ.).
Khramilin VN, Strokov IA, Davydov OS, Churyukanov MV. Diagnosis of diabetic polyneuropathy in primary care. Russian Journal of Pain. 2021;19(2): 47-53. (In Russ.). https://doi.org/10.17116/pain20211902147
Ziegler D, Papanas N, Schnell O, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021 Apr;12(4):464-475. https://doi.org/10.1111/jdi.13401
Barulin AE, Kurushina OV, Chernovolenko EP. Neuroreabilitation after stroke. Nervous Diseases. 2021;1:72-77. (In Russ.).
Chernovolenko EP, Karpukhina DV, Drushlyakova AA. Pain and asthenic syndromes in diabetic polyneuropathy. In the collection: Current problems of experimental and clinical medicine. Materials of the 75th Open Scientific-practical Conference of young scientists and students of the VolgSMU with international participation. 2017:112. (In Russ.).
Nellaiappan K, Preeti K, Khatri DK, Singh SB. Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies. Curr Diabetes Rev. 2022;18(1):e030821192146. https://doi.org/10.2174/1573399817666210309104203
Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. Journal of Diabetes Investigation. 2017 Sep;8(5):646-655.
Kurushina OV, Barulin AE, Karpukhina DV. Markers of peripheral nervous system lesion in diabetes mellitus. Medical Council. 2017;11:23-26. (In Russ.).
Khramilin VN, Davydov OS Painful diabetic polyneuropathy: evidence-based diagnosis and treatment. Russian Journal of Pain. 2021;19(4):44-59. (In Russ.). https://doi.org/10.17116/pain20211904144
Nesterova MV, Galkin VV. Diabetic polyneuropathy: pathogenesis, classification, clinical presentation, and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2013;5(2):97-105. (In Russ.). https://doi.org/10.14412/2074-2711-2013-2422
Zenker J, Ziegler D, Chart R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013;36(8):439-449. https://doi.org/10.1016/j.tins.2013.04.008
Biessels GJ, Bril V, Calcutt NA, et al. Phenotyping animal models of diabetic neuropathy: consensus of Diabetic Neuropathy Study Group. J Peripher Nerv Syst. 2014;19:77-87. https://doi.org/10.1111/jns5.12072
Samakidou G, Eleftheriadou I, Tentolouris A, et al. Rare diabetic neuropathies: It is not only distal symmetrical polyneuropathy. Diabetes Res Clin Pract. 2021 Jul;177:108932. https://doi.org/10.1016/j.diabres.2021.108932
Ziegler D. Diabetische Polyneuropathie. Internist (Berl). 2020 Mar;61(3):243-253. https://doi.org/10.1007/s00108-020-00770-8
Collection of reports «Preclinical studies of the substance and preparation Cellex 2007-2008». M.: Pharm-Synthesis CJSC. 2009:97. (In Russ.).
Romanova GA, Shakova FM, Barskov IV, et al. Effect of celleks on functional and morphological changes in experimental focal ischemia of prefrontal areas of the rat brain cortex. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2010;110(9-2):52-56. (In Russ.).
Belskaya GN, Krylova LG, Sokolov MA, Izmailov IA. Possibilities of the treatment of speech impairment in the acute stage of ischemic stroke using neuroprotective therapy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(9-2):60-63. (In Russ.). https://doi.org/10.17116/jnevro20151159260-63
Belskaya GN, Pizova NV, Sokolov MA, Izmailov IA Neuroprotection influence on course of cerebral stroke. Medical Council. 2016;11:34-39. (In Russ.). https://doi.org/10.21518/2079-701X-2016-11-26-31
Kulesh AA, Shestakov VV. Post-stroke cognitive impairment and the possibility of treatment with cellex. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2016;116(5):38-42. (In Russ.). https://doi.org/10.17116/jnevro20161165138-42
Kovalenko AV, Safronova MN. The effect of cellex on cognitive and speech impairments in the acute stage of stroke. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2015;115(1):40-44. (In Russ.). https://doi.org/10.17116/jnevro20151151140-44
Evzelman MA, Kazakov AYu, Kamchatnov PR, Umarova KhYa. The results of applying Cellex in patients after traumatic brain injury. Bulletin of Neurology, Psychiatry and Neurosurgery. 2016;10:23-29. (In Russ.).
Принята 17.06.2022